About this raise: Quadrant Biosciences is raising funds on Wefunder. The company has launched the world’s first saliva test for autism and is developing a pipeline of products, including tests for schizophrenia, anorexia nervosa, concussion, and Parkinson’s disease. The test for autism, The Clarifi ASD Test, is a game-changer in autism diagnosis and indicates the probability of a child having autism spectrum disorder. Quadrant Biosciences was founded by Richard Uhlig and has raised over $30 million in previous rounds of financing. The current round of crowdfunding has a minimum goal of $50,000 and a maximum goal of $1,070,000, and the proceeds will be used in developing more tests. Quadrant Biosciences has multiple international research partnerships and is working on developing a rapid saliva test for COVID-19.
Investment Overview
Invested : $411,608
Deal Terms
Total Commitments ($USD)
- Platform
- Wefunder
- Start Date
- 08/27/2020
- Close Date
- 02/18/2021
$50,000
$1,070,000
$100
Convertible Note
Series A
RegCF
Uncapped
20%
Company & Team
Company
- Year Founded
- 2015
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B
- Margin
- Medium
- Capital Intensity
- High
Financials
- Revenue +257% YoY
- $6,500,000
- Monthly Burn
- $608,022
-
Runway
- 2.1 months
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Company Funding & Growth
Funding history
Growth Charts
Revenue History
Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.
Valuation History
Price per Share History
Note: Share prices shown in earlier rounds may not be indicative of any stock splits.